Viz.ai has announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz ANEURYSM, a new algorithm that uses artificial intelligence (AI) to detect suspected cerebral aneurysms. The intention is to ensure that patients receive appropriate follow-up care by enabling hospital systems to make certain that patients are captured and that the treatment workflow across an entire health system is standardized after aneurysms are detected. Currently, it can be challenging for non-specialist centers to detect cerebral aneurysms and coordinate care for patients with this condition, and care pathways can be complex. Viz ANEURYSM will be the first AI-powered cerebral aneurysm detection solution designed to facilitate population screening and enhanced care management. A cerebral aneurysm is the ballooning or widening of a blood vessel in the brain and, if left untreated, can rupture, spilling blood into the surrounding tissue and causing a life-threatening subarachnoid hemorrhage. Viz.ai uses AI to accelerate care coordination. Its mission is to increase access to life-saving treatments and to transform healthcare using AI.
Read more here.